Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001104659-26-085430
Filing Date
2026-07-21
Accepted
2026-07-21 16:37:38
Documents
2

Document Format Files

Seq Description Document Type Size
1 424B3 tm2619649d5_424b3.htm 424B3 138205
2 GRAPHIC tm2619649d5_424b3img001.jpg GRAPHIC 5095
  Complete submission text file 0001104659-26-085430.txt   146529
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 424B3 | Act: 33 | File No.: 333-297532 | Film No.: 261190667
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)